Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
about
Adoptive cell therapy for sarcomaT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and OpportunitiesDendritic and mast cell involvement in the inflammatory response to primary malignant bone tumoursAerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacyHuman Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive SarcomaIGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.Associations of polymorphisms in NAT2 gene with risk and metastasis of osteosarcoma in young Chinese population.Genetically modified T-cell therapy for osteosarcomaSleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.Strategies and developments of immunotherapies in osteosarcomaClinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.Design and development of therapies using chimeric antigen receptor-expressing T cellsChimaeric antigen receptor T-cell therapy for tumour immunotherapy.Recent developments in transposon-mediated gene therapy.Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery.Adoptive immunotherapy for cancer.Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.IL-11 signaling as a therapeutic target for cancer.BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.Vectors and strategies for nonviral cancer gene therapy.Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Adoptive T-Cell Therapy for Solid Tumors.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Interleukin-11 receptor α is overexpressed in human osteosarcoma, and near-infrared-labeled IL-11Rα imaging agent could detect osteosarcoma in mouse tumor xenografts.Progress and opportunities for immune therapeutics in osteosarcoma.Tumor-targeting domains for chimeric antigen receptor T cells.Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cellsEngineering Chimeric Antigen Receptors.Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice.Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms.Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.Practical considerations for chimeric antigen receptor design and delivery.Preclinical and clinical advances in transposon-based gene therapy.Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells.
P2860
Q27009541-FA60E157-1452-4555-A4ED-06557C9262A4Q28074619-EAD1F0DB-817D-4862-AEAE-038ED15113A3Q33276145-A8C01B8B-EFFD-4EC5-9792-1F765E12069DQ34088081-D368ED75-3023-4EFA-99DC-53772A9B80BBQ34132358-3BC28957-6A9A-48DB-8004-525FA956A197Q35399080-42172CFB-AAC2-4088-9A11-A9D1ADCC8A05Q35598804-62F7D302-6A0D-40F2-B725-5873C81A2B4CQ35690979-781464DA-2337-43C2-A3F3-8C1047C35F95Q36111703-AE03D0FD-18CD-44C3-86BE-D19705D839C6Q36198232-CB626C64-0EDC-47C0-8CB9-CFE73C573055Q36214663-07BDB46D-FDCA-41D9-94FA-5C125FC78294Q36503128-D50C27CA-8A59-4C60-9B2A-921F04A706BEQ36682812-BC55C3EF-BF87-47D7-B60E-DA21BA9533F7Q37418289-DE86E7F7-D0AC-4AF0-8BE5-6F5D8E8BDD77Q37609801-B145F952-70AA-42FF-8DC8-E89F0E5C0DDBQ38017202-E42069D3-9F65-4927-A879-B094478582E5Q38120777-81267DBC-505A-4860-959D-2D41DC0D9A48Q38170496-307B7C04-6516-414D-94E6-F07606F29212Q38319552-000A43A7-5212-4374-9699-DE758B0B35F3Q38445355-84B38D01-0B5C-451D-BF90-F5A4BDBC01EFQ38683340-6D934FB6-5668-48B3-BB3C-CA6D5E7D4296Q38694798-40E5E935-242C-4BEE-B084-EEE99F251505Q38741113-A30E8292-E3DF-4976-B630-05AF89BD948EQ38754498-2B0E2E15-E4A2-45CE-BB0A-249C1E4E093EQ38783833-F7AA22C8-6363-4C32-B1D1-7237C5402851Q38927077-EBE8F3A3-6823-4623-B098-7EEF35DBD6E4Q38948905-5D80C58F-E206-4B4E-BC00-21CAECEF6DD6Q39045535-5581E85D-2794-4B33-9FBA-F72FD6A10CC1Q39133062-5D5E76E4-484C-4859-9E41-C85A20802970Q39276909-4200D3AF-BE27-46BF-8F0F-8EB420FA4CBBQ40398428-35CFCB46-38AA-47A7-827F-3B497C6ACC0AQ42576424-B7BA46EA-63A4-4D7E-87B0-BCA7BF513A5AQ44090164-F5A1B44F-3B5A-4D6D-A642-EC31FEE534D8Q45756098-C66E3C36-D467-4D8E-9B12-066E21EAF627Q45868559-A844A9CB-29C3-4E34-BA23-A99D2F6FA3E6Q45873802-5616E2A2-5562-4800-8F01-4A0C7845D44AQ47788129-453ECBCC-D71E-41F2-9B12-B4F217C64884Q50034069-1C622898-265D-4AFE-9386-CDEFE6711B1DQ52560420-DA6CEA7B-D598-48B3-90D5-1B8E960FD58BQ55129555-BC3E49F6-F0C8-42BA-9E89-8114E165A5C3
P2860
Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Genetically modified T cells t ...... osteosarcoma lung metastases.
@en
Genetically modified T cells t ...... osteosarcoma lung metastases.
@nl
type
label
Genetically modified T cells t ...... osteosarcoma lung metastases.
@en
Genetically modified T cells t ...... osteosarcoma lung metastases.
@nl
prefLabel
Genetically modified T cells t ...... osteosarcoma lung metastases.
@en
Genetically modified T cells t ...... osteosarcoma lung metastases.
@nl
P2093
P2860
P1433
P1476
Genetically modified T cells t ...... osteosarcoma lung metastases.
@en
P2093
Eugenie S Kleinerman
Gangxiong Huang
Helen Huls
Laurence Jn Cooper
Mario Hollomon
P2860
P304
P356
10.1158/0008-5472.CAN-11-2778
P407
P577
2011-11-10T00:00:00Z